NO20053959L - Medikament omfattende hoy-aktiv langtidsvarende beta-2-aqonist i kombinasjon med andre aktive bestanddeler - Google Patents

Medikament omfattende hoy-aktiv langtidsvarende beta-2-aqonist i kombinasjon med andre aktive bestanddeler

Info

Publication number
NO20053959L
NO20053959L NO20053959A NO20053959A NO20053959L NO 20053959 L NO20053959 L NO 20053959L NO 20053959 A NO20053959 A NO 20053959A NO 20053959 A NO20053959 A NO 20053959A NO 20053959 L NO20053959 L NO 20053959L
Authority
NO
Norway
Prior art keywords
active ingredients
combination
active
aqonist
medication
Prior art date
Application number
NO20053959A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053959D0 (no
Inventor
Roberta Razzetti
Fiorella Pastore
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32748803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20053959(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of NO20053959D0 publication Critical patent/NO20053959D0/no
Publication of NO20053959L publication Critical patent/NO20053959L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20053959A 2003-02-27 2005-08-25 Medikament omfattende hoy-aktiv langtidsvarende beta-2-aqonist i kombinasjon med andre aktive bestanddeler NO20053959L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03004184A EP1452179A1 (fr) 2003-02-27 2003-02-27 Nouveau combination d'un puissant agoniste beta 2 de longue duree et un corticosteroid
PCT/EP2004/001960 WO2004075896A1 (fr) 2003-02-27 2004-02-27 Medicament comportant un agoniste beta 2 de longue duree et tres puissant en combinaison avec d'autres ingredients actifs

Publications (2)

Publication Number Publication Date
NO20053959D0 NO20053959D0 (no) 2005-08-25
NO20053959L true NO20053959L (no) 2005-11-28

Family

ID=32748803

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053959A NO20053959L (no) 2003-02-27 2005-08-25 Medikament omfattende hoy-aktiv langtidsvarende beta-2-aqonist i kombinasjon med andre aktive bestanddeler

Country Status (31)

Country Link
US (1) US20070020190A1 (fr)
EP (3) EP1452179A1 (fr)
JP (1) JP2006519204A (fr)
KR (1) KR20050104367A (fr)
CN (2) CN100370986C (fr)
AR (1) AR043419A1 (fr)
AT (1) ATE401887T1 (fr)
AU (1) AU2004216472B2 (fr)
BR (1) BRPI0408047A (fr)
CA (1) CA2517321A1 (fr)
CY (1) CY1108360T1 (fr)
DE (1) DE602004015260D1 (fr)
DK (1) DK1603565T3 (fr)
EA (1) EA008828B1 (fr)
ES (1) ES2309503T3 (fr)
HR (1) HRP20050726A2 (fr)
MA (1) MA27630A1 (fr)
ME (1) MEP32208A (fr)
MX (1) MXPA05009007A (fr)
NO (1) NO20053959L (fr)
NZ (1) NZ541997A (fr)
PE (1) PE20050290A1 (fr)
PL (1) PL377814A1 (fr)
PT (1) PT1603565E (fr)
RS (1) RS20050615A (fr)
SA (1) SA04250122B1 (fr)
SI (1) SI1603565T1 (fr)
TN (1) TNSN05186A1 (fr)
UA (1) UA82217C2 (fr)
WO (1) WO2004075896A1 (fr)
ZA (1) ZA200506820B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
JP2007500676A (ja) * 2003-07-31 2007-01-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とベータ受容体刺激薬を含む吸入用薬剤
EP1654001A2 (fr) * 2003-08-05 2006-05-10 Boehringer Ingelheim International GmbH Medicament pour inhalation comprenant des steroides et un betamimetique
PT1670482E (pt) * 2003-09-16 2014-03-12 Takeda Gmbh Utilização de ciclesonida para o tratamento de doenças respiratórias
EP1863476B1 (fr) * 2005-03-16 2016-02-03 MEDA Pharma GmbH & Co. KG Combinaison d'anticholinergiques et d'antagonistes de recepteur de leukotriene permettant de traiter les maladies respiratoires
EP2484382A1 (fr) * 2005-03-30 2012-08-08 Schering Corporation Médicament à base d'un inhibiteur de la phosphodiestérase IV sous une forme adaptée à l'inhalation
CA2617286A1 (fr) * 2005-08-01 2007-02-08 Chiesi Farmaceutici S.P.A. Formulations pharmaceutiques comprenant un agoniste beta2 a longue duree d'action administrees par nebulisation
ATE529399T1 (de) * 2005-11-10 2011-11-15 Nicholas S Bodor Sanfte anticholinerge ester
NZ591969A (en) * 2005-12-21 2012-05-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-adrenoceptor agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
JP2010526763A (ja) * 2006-05-24 2010-08-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患を治療するための新規な長時間作用型の薬剤組成物
EP1953143A1 (fr) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Processus de préparation de monohydrochloride de 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-méthoxyphényl)-1-méthyléthyl]amino]éthyl]-2(1H)-quinolinone
EP2124915A2 (fr) * 2007-02-19 2009-12-02 Cipla Limited Combinaisons pharmaceutiques
EP2534957B1 (fr) 2007-12-14 2015-05-27 AeroDesigns, Inc Administration de produits sous forme d'aérosols
EP2100599A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2100598A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
US9623000B2 (en) 2008-07-31 2017-04-18 Dekel Pharmaceuticals Ltd Compositions and methods for treating inflammatory disorders
WO2010097188A1 (fr) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Particules pour inhalation comprenant un sel de carmotérol et un corticostéroïde
BRPI1008165B1 (pt) * 2009-05-25 2020-02-27 Chiesi Farmaceutici S.P.A. Uma combinação terapêutica compreendendo um surfactante pulmonar e um esteróide
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
PL3111927T3 (pl) 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy
WO2011136753A1 (fr) * 2010-04-26 2011-11-03 Mahmut Bilgic Combinaison de carmotérol et de fluticasone utilisée pour le traitement de maladies respiratoires
CN102247597B (zh) * 2010-05-19 2015-01-07 天津金耀集团有限公司 一种糖皮质激素与支气管扩张剂的吸入剂
CN103096897A (zh) * 2010-07-16 2013-05-08 希普拉有限公司 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物
WO2012010854A1 (fr) 2010-07-23 2012-01-26 Cipla Limited Composition pharmaceutique
CN102416179B (zh) * 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
TWI399202B (zh) * 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
EP2510928A1 (fr) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires
EP2968312B1 (fr) * 2013-03-15 2018-01-31 Verona Pharma PLC Association de médicaments
CA2961410C (fr) 2014-09-16 2023-07-11 India Globalization Capital, Inc. Composition cannabinoide et methode de traitement de la douleur
US11026918B2 (en) 2014-11-24 2021-06-08 The Board Of Trustees Of The University Of Illinois Method of preventing or treating a pulmonary disease or condition
US10751300B2 (en) 2015-01-25 2020-08-25 India Globalization Capital, Inc. Composition and method for treating seizure disorders
WO2017027651A1 (fr) * 2015-08-12 2017-02-16 India Globalization Capital, Inc. Méthode et composition pour traiter la cachexie et les troubles de l'alimentation
EP3471746A4 (fr) 2016-06-15 2020-02-26 India Globalization Capital, Inc. Méthode et composition pour traiter des troubles epileptiques
CN115337311B (zh) * 2022-09-26 2023-05-09 南京恒道医药科技股份有限公司 一种治疗呼吸系统疾病的组合物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
WO1998041193A1 (fr) * 1997-03-20 1998-09-24 Schering Corporation Preparation d'agglomerats de poudre
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US20020081266A1 (en) * 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
AU2000250701B2 (en) * 2000-05-22 2004-07-01 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
ES2342463T3 (es) * 2002-03-01 2010-07-07 Chiesi Farmaceutici S.P.A. Formulacion superfina de formoterol.
EP1340492A1 (fr) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Formulations d'aérosol pour l'administration par voie pulmonaire de medicaments avec effet systémique
EP1595531A1 (fr) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Formulation d'une solution pharmaceutique stable pour aérosols doseurs sous pression

Also Published As

Publication number Publication date
PE20050290A1 (es) 2005-05-26
EA200501108A1 (ru) 2006-04-28
DK1603565T3 (da) 2008-11-10
EP1603565B1 (fr) 2008-07-23
CN101244063A (zh) 2008-08-20
AU2004216472B2 (en) 2009-08-06
HRP20050726A2 (en) 2006-02-28
SA04250122B1 (ar) 2009-03-11
NZ541997A (en) 2008-12-24
HK1087009A1 (en) 2006-10-06
US20070020190A1 (en) 2007-01-25
CY1108360T1 (el) 2014-02-12
NO20053959D0 (no) 2005-08-25
ZA200506820B (en) 2006-11-29
AU2004216472A1 (en) 2004-09-10
SI1603565T1 (sl) 2008-10-31
JP2006519204A (ja) 2006-08-24
ATE401887T1 (de) 2008-08-15
DE602004015260D1 (de) 2008-09-04
ES2309503T3 (es) 2008-12-16
MA27630A1 (fr) 2005-11-01
EP1452179A1 (fr) 2004-09-01
MEP32208A (en) 2010-10-10
WO2004075896A1 (fr) 2004-09-10
UA82217C2 (uk) 2008-03-25
PL377814A1 (pl) 2006-02-20
KR20050104367A (ko) 2005-11-02
EP1603565A1 (fr) 2005-12-14
AR043419A1 (es) 2005-07-27
BRPI0408047A (pt) 2006-02-14
PT1603565E (pt) 2008-10-06
CA2517321A1 (fr) 2004-09-10
CN1753678A (zh) 2006-03-29
MXPA05009007A (es) 2005-10-18
RS20050615A (sr) 2007-09-21
EP1834643A2 (fr) 2007-09-19
EA008828B1 (ru) 2007-08-31
EP1834643A3 (fr) 2007-10-24
CN100370986C (zh) 2008-02-27
TNSN05186A1 (en) 2007-06-11

Similar Documents

Publication Publication Date Title
NO20053959L (no) Medikament omfattende hoy-aktiv langtidsvarende beta-2-aqonist i kombinasjon med andre aktive bestanddeler
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
EA200500902A1 (ru) Порошковые лекарственные средства, содержащие соль тиотропия и ксинафоат салметерола
HUP0402075A2 (hu) Készítmények nátha kezelésére
EA200501105A1 (ru) Фармацевтическая композиция
US20230058134A1 (en) Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
CA2519679A1 (fr) Combinaison a effet synergique comprenant le roflumilast et un agent anticholinergique choisi parmi l'ipratropium, l'oxitropium et le tiotropium sous forme saline pour le traitement de maladies respiratoires
EA200600854A1 (ru) Новые соли тиотропия, способ их получения, а также содержащие их лекарственные композиции
BR112023002778A2 (pt) Ácido (1r,3s)-3-((5-ciano-4-feniltiazol-2-il) carbamoil) ciclopentano-1-carboxílico e derivados do mesmo para uso no tratamento de doenças das vias aéreas
US20080207667A1 (en) Use of nalbuphine and related compounds to treat symptoms of respiratory problems
JP2003321357A (ja) 内服用組成物
EA200500864A1 (ru) Новый, содержащий тиотропий порошковый препарат для ингаляции
TNSN05131A1 (en) New synergistic combination comprising roflumilast and formoterol
WO2003039439A3 (fr) Pyrazolopyrimidinones deuterees et medicaments contenant ces composes
EP1411956B8 (fr) Utilisation de polysaccharides sursulfates comme inhibiteurs du hiv
DE60308497D1 (de) Pulverzubereitungen zur inhalation
Eccles Over the counter medicines for colds
HRP20050580B1 (hr) Sinergistiäśki uäśinak kombinacije roflumilasta i (r,r)-formoterola
US20080293804A1 (en) Pharmaceutical Nasal Spray Formulation of Acetaminophen (paracetamol)
EA200501765A3 (ru) Средство для лечения болезней суставов
PT1490049E (pt) Citalopram para o tratamento da pre3ssao sanguinia elevada.
TH77905A (th) ยาชนิดใหม่ซึ่งประกอบรวมด้วย เบตา2 -อะโกนิสต์ที่มีการออกฤทธิ์นาน และมีศักยภาพสูงในการใช้ร่วมกับส่วนประกอบออกฤทธิ์อื่นๆ

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application